Evidence Synthesis
MEDPLUS experienced a 25.8% gross margin, accelerating from 2.94% in the previous quarter.
Loading stock analysis…
Loading stock analysis…
Evidence Synthesis
Last synthesized: 16 Sept 2026, 02:37
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
MEDPLUS experienced a 25.8% gross margin, accelerating from 2.94% in the previous quarter.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 25.8 % | 2.94 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 2.94 % | 2.91 | ▲ |
| REVENUE_GROWTH_YOY | 21.8 % | -21.8 | ▲ |
| EPS_ACTUAL | 4.62 INR | 4.81 | ▼ |
| EPS_SURPRISE_PERCENT | 0.113 % | 0.061 | ▲ |
| PRICE_CHANGE_PERCENT | -0.583 % | — | - |
| DAILY_VOLUME | 61,605 shares | 2,14,970 | ▼ |
| CLOSE_PRICE | 656.3 INR | 660.15 | ▼ |
| NEWS_SENTIMENT_SCORE | 1 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 2 count | 5 | ▼ |
| TARGET_PRICE_PREMIUM | 54.37 % | — | - |